Rationally designed Gla-domainless FXa as TFPI bait in hemophilia
Preprint
Abstract
Gla-domainless factor Xa (GD-FXa) was proposed as a trap to the endogenous anticoagulant Tissue Factor Pathway Inhibitor (TFPI) to restore thrombin generation in hemophilia. Using computational chemistry and experimental approaches, we previously showed that S195A GD-FXa also binds TFPI and restores ex vivo coagulation in hemophilia plasmas. To design a GD-FXa variant with improved anti-TFPI activity and identify suitable sites for mutagenesis, we performed molecular dynamics simulations. The calculations identified residues R150 FXa and K96 FXa as cold-spots of interaction between GD-FXa and the K2 domain of TFPI. In the three-dimensional model, both residues are facing TFPI hydrophobic residues and are thus potential candidates for mutagenesis into hydrophobic residues to favor an improved protein-protein interaction. Catalytically inactive GD-FXa variants containing the S195A mutation and additional mutations as K96Y, R150I, R150G and R150F were produced to experimentally confirm these computational hypotheses. Among these mutants, the R150F FXA showed increased affinity for TFPI as theoretically predicted, and was also more effective than S195A GD-FXa in restoring coagulation in FVIII deficient plasmas. Moreover, the R150 mutants lost interaction with antithrombin, which is favorable to extend their half-life.Keywords
This publication has 26 references indexed in Scilit:
- The growth of siRNA-based therapeutics: Updated clinical studiesBiochemical Pharmacology, 2021
- 2021 clinical trials update: Innovations in hemophilia therapyAmerican Journal of Hematology, 2020
- When innovation goes fast. The case of hemophiliaCurrent Opinion in Pharmacology, 2019
- Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophiliaInternational Journal of Hematology, 2018
- Antithrombin–S195A factor Xa‐heparin structure reveals the allosteric mechanism of antithrombin activationThe EMBO Journal, 2006
- Empirical force fields for biological macromolecules: Overview and issuesJournal of Computational Chemistry, 2004
- Serine Protease Mechanism and SpecificityChemical Reviews, 2002
- An Overview of Serine ProteasesCurrent Protocols in Protein Science, 2001
- Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitorNature, 1989
- CHARMM: A program for macromolecular energy, minimization, and dynamics calculationsJournal of Computational Chemistry, 1983